Notable Outcomes of Selinexor-Based Triplet Therapy Addressed in RRMM
February 22nd 2024Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.
Watch
Upfront Nivolumab/Chemo Produces Durable Responses in Urothelial Carcinoma
February 16th 2024Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.
Watch
Real-World Survival Analysis of Apalutamide vs Enzalutamide in mCSPC
February 14th 2024Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.
Watch